Eliem Therapeutics Inc

NASDAQ:ELYM  
16.24
-0.04 (-0.25%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Eliem Therapeutics Inc Stock, NASDAQ:ELYM

23515 NE Novelty Hill Road, Suite B221, 125, Redmond, Washington 98053
United States of America
Phone: +1.425.276.2300
Number of Employees: 13

Description

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Redmond, WA.